Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

University of Toronto

$17,500.00

Glioblastoma Epigenetic Biomarker Elucidation via Genome Methylome Profiling

FY 2022-23

Summary
Glioblastomas are an aggressive form of cancer located in the brain and spinal cord. They have a very low survival rate, with only 1% of patients surviving past the 10-year mark. There is an urgent need to identify biomarkers for early detection and potential therapeutic targeting. Epigenetic biomarkers are a new technology within the cancer diagnostic field where we identify patterns of DNA methylation in glioblastoma that promote oncogenesis and/or treatment resistance. To identify such biomarkers, we would take post-mortem brain samples of glioblastoma patients and do methylome profiling on them, which would allow us to identify differences in DNA methylation patterns in glioblastoma versus control samples. DNA methylation is the cell's mechanism for up- or down-regulating expression of certain genes by increasing or decreasing the accessibility of transcription factors to those genes. Once we find patterns of differential methylation across glioblastoma samples, we will integrate that data with other sequencing information, as well as clinical and environmental data to make predictions about the affect of that differential methylation on the cell. We will then test these predictions in cell lines and transgenic mouse samples. The exact methods we will use in this part of the study will depend on the kind of information we gather from the methylome profiling and data integration stage. But, it will likely involve gene knockouts or over-expression models that we can use to evaluate the affect of differential methylation on specific genes. All together, this study will allow us to identify potential biomarkers for early detection and therapeutic targeting.
Program
Master's Award: Canada Graduate Scholarships
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
486487
Name
Fatima Hira
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Glioblastoma Epigenetic Biomarker Elucidation via Genome Methylome Profiling
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Biomarkers; Brain Cancer; Diagnostic; Drug Development; Early Detection; Epigenetics; Glioblastoma; Methylation; Multi-Omics; Therapeutic
Abstract
Glioblastomas are an aggressive form of cancer located in the brain and spinal cord. They have a very low survival rate, with only 1% of patients surviving past the 10-year mark. There is an urgent need to identify biomarkers for early detection and potential therapeutic targeting. Epigenetic biomarkers are a new technology within the cancer diagnostic field where we identify patterns of DNA methylation in glioblastoma that promote oncogenesis and/or treatment resistance. To identify such biomarkers, we would take post-mortem brain samples of glioblastoma patients and do methylome profiling on them, which would allow us to identify differences in DNA methylation patterns in glioblastoma versus control samples. DNA methylation is the cell's mechanism for up- or down-regulating expression of certain genes by increasing or decreasing the accessibility of transcription factors to those genes. Once we find patterns of differential methylation across glioblastoma samples, we will integrate that data with other sequencing information, as well as clinical and environmental data to make predictions about the affect of that differential methylation on the cell. We will then test these predictions in cell lines and transgenic mouse samples. The exact methods we will use in this part of the study will depend on the kind of information we gather from the methylome profiling and data integration stage. But, it will likely involve gene knockouts or over-expression models that we can use to evaluate the affect of differential methylation on specific genes. All together, this study will allow us to identify potential biomarkers for early detection and therapeutic targeting.
Competitiondate
202212
Approvedterm2
1 yr 0 mth
Pinamesdelim
Fatima, Hira
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~